1. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353(5):487-497.
2. Dimatteo MR: Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004, 42(3):200-209.
3. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA: Self- report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006, 10(3):227-245.
4. Berg KM, Arnsten JH: Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006, , Suppl 1: 79-87.
5. Bangsberg DR: Less than 95% adherence to nonnucleoside reverse- transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43(7):939-941.
6. Bangsberg DR: Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008, 197(Suppl 3):272-278.
7. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O’shaughnessy MV, Hogg RS: Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002, 16(15):2065-2072.
8. Glass TR, DE Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006, 41(3):385-392.
9. Stone VE, Jordan J, Tolson J, Miller R, Pilon T: Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self- report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36(3):808-816.
10. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR: Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005, 16:38-41.
11. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, MAKHEMA J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34(3):281-288.
12. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, SUTER F: Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005, 40:158-163.
13. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005, 191(3):339-347.
14. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, Higgins A, Zorrilla C, Landesman S, Serchuck L, LARUSSA P: Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008, 20(8):958-968.
15. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006, 43:78-84.
16. Girard P, Blaschke TF, Kastrissios H, Sheiner LB: A Markov mixed effect regression model for drug compliance. Stat Med 1998, 17(20):2313-2333.
17. Wong D, Modi R, Ramanathan M: Assessment of Markov-Dependent Stochastic Models for Drug Administration Compliance. Clin Pharmacokinet 2003, 42:193-204.
18. Sun J, Nagaraj HN, Reynolds NR: Discrete Stochastic Models for Compliance Analysis Based on an AIDS Clinical Trial Group (ACTG) Study. Biomedical Journal 2003, 49:731-741.
19. Grimmett GR, Stirzaker DR: Probability and Random Processes New York: Oxford University Press; 1992.
20. Seber GAF: Multivariate observations New York: Wiley; 1984.
21. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, Levin J, Katabira E, Gilks C, Todd J: Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2008, 48(4):468-475.
22. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, Jacobson LP: Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007, 45(10):1377-1385. doi:10.1186/1742-5573-8-3 Cite this article as: Kiwuwa-Muyingo et al.: Clustering based on adherence data. Epidemiologic Perspectives & Innovations 2011 8:3.